ArticleInternational journal of retina and vitreous2026
Predictors of response to bevacizumab monotherapy in polypoidal choroidal vasculopathy: a 12-month retrospective study.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo identify baseline predictors of anatomical response after intravitreal bevacizumab in polypoidal choroidal vasculopathy (PCV) and to evaluate anatomical and visual outcomes over 12 months.
methodsThis retrospective study included 81 eyes with PCV treated with three consecutive monthly intravitreal bevacizumab injections. Patients were classified as good or poor responders based on optical coherence tomography (OCT) findings at month 3. Baseline demographic, clinical, and imaging parameters were compared between groups, and predictors of poor response were identified using multivariable regression. Visual acuity (VA), central retinal thickness (CRT), subretinal fluid (SRF), and pigment epithelial detachment (PED) height were analyzed within and between groups through month 12.
resultsForty eyes (49.4%) were poor responders and 41 (50.6%) were good responders. Greater baseline SRF height and thinner SFCT were independent predictors of poor response (RR per 100 μm: 1.27 and 0.71 respectively; AUC = 0.74). Good responders showed significant VA improvement (0.64 ± 0.08 vs. 0.48 ± 0.06 logMAR, p < 0.001) and CRT reduction (419.5 ± 24.3 vs. 285.5 ± 14.1 μm, p < 0.001) at month 3, and these were maintained at month 12. Among good responders, 75% continued bevacizumab injections (non-switch group) and sustained favorable outcomes. In contrast, 86% of poor responders switched to other medications (switch group), achieving significant VA gain, CRT reduction, and further SRF with PED reduction by month 12. The non-switch group required fewer injections (5.8 ± 2.5 vs. 7.8 ± 3.0 injections; p < 0.001) and achieved longer treatment intervals (11.7 ± 9.0 vs. 7.8 ± 3.0 weeks; p = 0.046) than the switch group.
conclusionsApproximately half of PCV eyes demonstrated a favorable response to bevacizumab monotherapy. Baseline SRF height and SFCT were significant predictors of treatment response. Early assessment after three monthly bevacizumab injections allowed for the differentiation between relatively mild and a more severe disease requiring more frequent and sustained anti-VEGF injections. Switching of anti-VEGFs was associated with improved outcomes in poor responders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.